Chronic hepatitis C also affects the liver and is caused by the hepatitis C virus. The virus infects liver cells and can cause severe inflammation of the liver with long-term complications. hepatitis C infections are common worldwide and it is estimated that about 3 per cent of the world's population has hepatitis C.

Acute versus chronic
Hepatitis C infection is usually acute initially but can develop into a chronic condition. Approximately 15 per cent to 45 per cent of people clear the virus completely during the acute phase and 55 per cent to 85 per cent of patients who have acute hepatitis C may develop further serious liver diseases, including cirrhosis and liver cancer.

The hepatitis C virus is usually spread through blood such as sharing needles or other equipment associated with injecting drug use. It can also be spread through blood infusions, organ transplants and although now less common, blood contamination in medical settings.

Most people with acute hepatitis C do not experience any symptoms and therefore, may risk spreading the virus. If there are symptoms, they usually occur anytime between two weeks to six months after initial exposure. Symptoms may include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-coloured bowel movements, joint pain and jaundice.

Diagnosis and treatment
Diagnosis for hepatitis C is done through specific blood tests that are not typically done during regular physician exams. A screening test is typically done to look for "antibodies" of hepatitis C virus. If antibodies are found, separate blood tests are needed to determine if the infection has cleared or has become a chronic infection.

Acute hepatitis C cases typically go untreated as they do not have symptoms. For chronic cases, treatment options include antiviral medication. There is no vaccine for hepatitis C virus. The best way to prevent hepatitis C is by avoiding behaviours that can spread the infection, especially by sharing drug injection equipment.

FaLang translation system by Faboba


>> CEVHAP Strategy 2017-2021



NOhep is a global, grassroots movement aimed at bringing all stakeholders together to eliminate viral hepatitis by 2030. It has been developed to create global awareness of the disease, similar to the red ribbon for HIV/AIDS, and was launched in 2016. NOhep firmly positions itself at the forefront of the elimination conversation, showcasing exemplary leadership, fostering on-the-ground innovative solutions and taking action to support the policy changes needed to eliminate this cancer-causing illness by 2030. Being a part of NOhep means being part of the solution. (To find out more about the development of this exciting initiative, watch this short video:

Viral Hepatitis
  Globally, 2 billion people have been
infected with hepatitis B virus, with an
estimated 600,000 dying each year . . .
  The number of people with chronic
hepatitis C and more advanced liver
disease or cirrhosis, is projected to
increase by 38% between 2006 and 2015
unless the number of people being
treated increases substantially.
  There is no vaccine for hepatitis C but
approximately 80% of patients who are
able to complete recommended
treatment, are cured . . .
World Hepatitis Day
July 28
WHD 2013

One million people die from viral 
hepatitis in Asia Pacific every year.
urges governments to embrace WHO's
new global framework for action.
                                >> READ MORE

Why hepatitis policy matters - the story of Baltazar Lucas  
Video What are the dangers of viral #hepatitis? Hear what #CEVHAP Chair Prof Ding-Shinn Chen had to say to the Wall Street Journal.
A Message from DS Chen
Chairman, CEVHAP


Connect with usconnect with CEVHAP